Yesterday was brutal and there is really little to say about it as we are clearly in the middle of a massive correction if not outright bear market. I suspect.
It is unfortunate that the earnings weeks comes as the market seems to want to collapse. Industrial earnings are finally seeing the impact of the trade policies and now apparently.
We finally have some M&A in the sector but I am not convinced it will have a very broad effect. While it is not a small deal, the $2B or.
Chimera Research Group: What sets Briacell apart from other immuno-oncology approaches? Dr. William V. Williams, President and CEO of Briacell: Briacell is developing a novel cancer immunotherapy based on a.
Not a lot in terms of news but certainly in terms of action. The selloff has been brutal but I think we are much closer to a bottom than many.
It was certainly not a great start to the week and the sector really needs a turnaround Tuesday to pan out. Interestingly, the pharma and large cap bios did OK.
There is not a lot of news today, so I will keep it relatively quick. I am really not starting to like the way the sector is trading. The XBI.
We continue to see the disconnect between the IBB and XBI, where the large caps are outperforming the SMID. Given that the previous range break on the IBB did not.
The sector appears to be gaining some momentum but we need to see the strength continue and ideally broaden. Positive data being rewarded is good as there have been times.
An interesting start to the week, although we still like real M&A or business development. Unlike previous weeks, however, there is actually some interesting news to discuss. The sector is.
Still a boring market in terms of news. The sector appears to have successfully defended the bottom end of its range but one could argue it done so simply by.
The sector struggled yesterday and it still looks like testing the bottom on the range is possible. Perhaps the China tariffs news cleared the market a little and we might.